EFICACY OF ZINC SUPLEMENTATION AS ADJUVANT THERAPY IN CHILDREN 6- 60 MONTHS OLD WITH PNEUMONIA
on
Authors:
I Gusti Lanang Sidiartha, I Kompiang Gede Suandi, Ida Bagus Subanada, Ni Putu Siadi Purniti, AA Raka Karsana
Abstract:
“Morbidity and mortality rates of childhood pneumonia is still high, especially in developing countries. Many efforts are done to decrease the morbidity and mortality rate and one of them is zinc supplementation as adjuvant therapy. The aim of the study is to find the effectiveness of zinc supplementation as adjuvant therapy in childhood pneumonia. The randomized controlled trial study was done on 33 patients with pneumonia at Sanglah Hospital Denpasar. Intervention group received 20 mg zinc elemental each day. Time for recovery and length of hospital stay were compared between zinc and placebo groups. The different was significant if the P value < 0.05. Time for recovery in zinc group and placebo group was 4 days and 3.4 days, respectivelly. Length of hospital stay was 5.9 days in zinc group and 5.6 days in placebo group. The different was not significant. Conclusion is zinc supplementation as adjuvant therapy in childhood pneumonia is not effective to decreased the time for recovery and length of hospital stay. (MEDICINA 2012;43:9-14).”
Keywords
Keyword Not Available
Downloads:
Download data is not yet available.
References
References Not Available
PDF:
https://jurnal.harianregional.com/medicina/full-4943
Published
2021-11-09
How To Cite
SIDIARTHA, I Gusti Lanang et al. EFICACY OF ZINC SUPLEMENTATION AS ADJUVANT THERAPY IN CHILDREN 6- 60 MONTHS OLD WITH PNEUMONIA.Medicina, [S.l.], v. 43, n. 1, mar. 2013. ISSN 2540-8321. Available at: https://jurnal.harianregional.com/medicina/id-4943. Date accessed: 28 Aug. 2025.
Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian
Issue
Vol 43 No 1 (2012): Januari 2012
Section
Articles
Copyright
This work is licensed under a Creative Commons Attribution 4.0 International License
Discussion and feedback